Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine at AACR 2024

On March 5, 2024 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported that it will present a poster on updated data from the ongoing randomized Phase I trial of TG4050 at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (AACR) (Free AACR Whitepaper) (Press release, Transgene, MAR 6, 2024, View Source [SID1234640809]). The AACR (Free AACR Whitepaper) will take place in San Diego, California, USA, from April 5 to 10, 2024.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster details

Title: Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers

· Session title: Late-Breaking Research: Clinical Research 3

· Poster and abstract number: LB401

· Date and Time: Wednesday April 10, 2024, 9:00 a.m. – 12:30 p.m. PDT

· Location: Poster Section 52, Board number 2

· Authors : A. Lalanne, C. Jamet, JP Delord, C. Ottensmeier, C. Le Tourneau, A. Tavernaro, G. Lacoste, B. Bastien, M. Brandely, B. Grellier, E. Quemeneur, Y. Yamashita, O. Kousuke, N. Yamagata, Y. Tanaka, K. Onoguchi, I. G. Pait, B. Malone, O. Baker, P. Brattas, M. Gheorghe, R. Stratford, T. Clancy, K. Bendjama, O. Lantz

The abstract will be available on the AACR (Free AACR Whitepaper) website April 5, 2024, at 3:00 p.m. ET / 9:00 p.m. CET.

TG4050 is an individualized immunotherapy being developed for solid tumors that is based on Transgene’s myvac technology and powered by NEC’s longstanding artificial intelligence (AI) and machine learning (ML) expertise. TG4050 is being evaluated in a randomized multicenter Phase I clinical trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers (NCT04183166). Transgene and NEC plan to continue the development of TG4050 in this indication with a Phase II extension of the trial expected to start in 2024. TG4050 is being jointly developed by Transgene and NEC.